Alumis Inc. (ALMS) analyst actions
Rating and price-target actions on ALMS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALMS overview →
1 measured ALMS analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis | Press release | +0.40% | +2.24% |
Keep exploring
More ALMS: earnings → · SEC filings → · ALMS overview →